Annual report pursuant to Section 13 and 15(d)

Description of Business (Details)

v3.20.4
Description of Business (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2020
USD ($)
shares
Mar. 31, 2020
USD ($)
program
Feb. 28, 2019
USD ($)
Jul. 31, 2018
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Investment in non-marketable securities           $ 2,000 $ 0 $ 0
Nestec Ltd. (Nestle Health Sciences) | CDX-6114                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Revenue recognized     $ 3,000   $ 3,000      
Nestec Ltd. (Nestle Health Sciences) | CDX-6114 | Collaborative Arrangement                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Milestone payment amount     $ 1,000 $ 4,000        
Takeda                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Number of initial programs | program   3            
Number of additional programs | program   4            
Collaboration payment   $ 8,500            
Molecular Assemblies, Inc. | Series A Preferred Stock                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Investment owned, balance (in shares) | shares 1,587,050              
Investment in non-marketable securities $ 1,000